For decades, lung cancer has been synonymous with smoking; yet growing evidence challenges this assumption. Today, never-smokers account for up to 25% of non-small cell lung cancer (NSCLC) cases worldwide, establishing them as a distinct and increasingly recognized at-risk population[1].
While tobacco remains the dominant overall cause, NSCLC in never-smokers arises from a complex interplay of environmental exposures, genetic susceptibility, and biological risk factors that often go unrecognized. Because these individuals are not traditionally considered at risk, diagnosis frequently occurs at more advanced stages, when treatment options are more limited and outcomes poorer.
This epidemiological shift signals an urgent need to rethink how lung cancer risk is understood, identified, and addressed.
A Convergence of Overlooked Risk Factors
In never-smookers, NSCLC rarely results from a single cause. Instead, risk accumulates gradually through chronic exposures and underlying predispositions.
Second-hand smoke remains a significant contributor, increasing lung cancer risk by 20-30% due to prolonged inhalation of carcinogens present in tobacco emissions[2].
Radon gas represents another major but often invisible threat. This naturally occurring radioactive gas seeps into buildings from soil and rock, emitting alpha particles that damage lung tissue DNA. Radon exposure accounts for approximately 10% of lung cancer cases in never-smokers, making home testing and corrective measures (such as installing ventilation or radon reduction systems) essential preventive steps if elevated levels are detected[3].
Air pollution is also a critical driver. Fine particulate matter (PM2.5), generated by traffic, industrial activity, and biomass burning, penetrates deep into the lungs, triggering inflammation, oxidative stress, and genetic mutations. This risk is particularly pronounced in densely populated urban regions, where exposure is chronic and cumulative.
Occupational hazards further compound susceptibility. Long-term exposure to asbestos, silica, diesel exhaust, arsenic, and industrial chemicals (common in mining, manufacturing, and construction) has been strongly linked to increased NSCLC risk.
Genetics also play a defining role; never-smokers with NSCLC are significantly more likely to harbour specific molecular alterations, particularly mutations in the EGFR gene, which occur in up to 50% of Asian never-smokers. Family history, inherited genetic variants (e.g. KRAS), and hormonal influences, especially estrogen signaling in postmenopausal women, further shape individual risk profiles.
Additional contributors, including chronic lung disease such as chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, prior infections, and even prolonged exposure to cooking fumes indoors, add further lays of risk[4].
Taken together, these factors create a distinct disease pathway: one that develops largely outside the traditional smoking paradigm.
A Global Rise that is Reshaping Lung Cancer Epidemiology
The growing incidence of NSCLC in never-smokers is not anecdotal; it is measurable and accelerating.
Today, never-smokers represent between 15% and 25% of all lung cancer cases globally. Since 2000, diagnoses in this group have increased substantially, by between 30% and 50%, particularly in urban regions across Asia and North America[5].
The trend is especially striking among women. In East Asia, more than half of women diagnosed with NSCLC have never smoked[6]. Urbanization, environmental exposures, and demographic shifts all contribute to this rise.
Air pollution is now recognized as one of the most important drivers of this increase. Chronic exposure to PM2.5 and nitrogen dioxide contributes to genetic alterations associated with lung cancer, including EGFR mutations that define many never-smoker tumors[7].
Indoor pollution, particularly from biomass cooking fuels used in poorly ventilated environments, further elevates lifetime risk[8].
Meanwhile, radon exposure, occupational inhalants, and second-hand smoke continue to contribute to disease burden, even as smoking prevalence declines[9].
The result is a growing population developing lung cancer without ever smoking — a reality that challenges long-standing assumptions about who is at risk.
A Biologically Distinct Disease
NSCLC in never-smokers is not simply lung cancer without tobacco exposure. It is a biologically distinct disease.
Tumors in never-smokers are likelier to be adenocarcinomas arising in the lung periphery and driven by specific molecular alterations, including EGFR, ALK, ROS1, and HER2 mutations. These molecular differences have important clinical implications. They influence how the disease develops, how it progresses, and how it responds to treatment, often making targeted therapies more effective than conventional chemotherapy.
Genetic susceptibility also plays an important role, with germline variants in cancer-related genes such as EGFR, TP53, and HER2 associated with increased likelihood of NSCLC in never-smokers[10]. Consistent with this, individuals with a family history of lung cancer face elevated risk even in the absence of smoking. Hormonal signaling, particularly involving estrogen, may further influence tumor development, helping explain the higher incidence observed in women.
Chronic inflammation caused by environmental exposures further contributes to cancer development. Air pollutants such as PM2.5, nitrogen oxides, and volatile organic compounds can trigger persistent inflammatory and epigenetic changes in lung tissue[11]. In heavily polluted urban regions, such as megacities in East and South Asia, these exposures have been associated with a 20-40% increase in NSCLC risk among never-smokers. Indoor biomass fuels, occupational inhalants, and radon exposure similarly promote long-term tissue damage, fibrosis, and DNA alterations that create conditions favorable to tumor formation.
by pollution, infection, or lung disease further creates an environment conducive to cancer development.
Together, these findings reinforce the need to view NSCLC in never-smokers as a distinct clinical and public health challenge.
Why this Shift Demands a New Approach
Despite this growing risk, lung cancer awareness, screening, and diagnostic strategies remain largely focused on smokers. This gap has real consequences.
Never-smokers, and the clinicians treating them, are often less likely to suspect lung cancer, delaying diagnosis. Symptoms such as persistent cough, fatigue, or shortness of breath may be attributed to less serious conditions, allowing disease to progress unchecked.
Screening guidelines also remain heavily tied to smoking history. Low-dose CT screening, proven to detect lung cancer and reduce mortality, is currently recommended primarily for individuals with significant smoking exposure.
Yet emerging evidence suggests that targeted screening in high-risk never-smoker populations, such as those with high pollution exposure, genetic predisposition, or occupational risk could significantly improve early detection and survival.
This includes:
• Increasing awareness that lung cancer can occur in never-smokers
• Expanding risk assessment beyond smoking history alone
• Integrating environmental and genetic risk factors into screening decisions
• Improving access to molecular profiling to guide precision treatment
• Strengthening environmental protections to reduce preventable exposures
Rethinking Lung Cancer Risk
The rise in NSCLC among never-smokers represents a significant shift in how lung cancer risk is understood. It challenges outdated assumptions, exposes gaps in prevention and detection, and it highlights the need for a broader, more inclusive understanding of lung cancer risk.
Most importantly, it reinforces a critical reality: smoking is not a prerequisite for developing lung cancer. Recognizing this shift is essential to ensuring earlier diagnosis, more effective treatment, and better outcomes for a growing, and often overlooked, population.
Screening paradigms require expansion beyond smoker-centric low-dose CT (LDCT) criteria, like the outdated 30-pack-year threshold, to encompass non-smoker high-risk strata such as those in radon hotspots or polluted megacities. Pilot programs in Asia demonstrate that inclusive LDCT offered annually to genetically susceptible urban non-smokers yields 15-20% mortality reductions via early detection of indolent nodules amenable to sub lobar resection or targeted therapies. Policy integration of genomic profiling and exposure mapping ensures equitable access, transforming NSCLC from a fatal inevitability into a manageable chronic condition for this burgeoning cohort.
References:
1. Hendriks, L. E., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G. & Reck, M. (2024). Non-small-cell lung cancer. Nature Reviews Disease Primers, 10 (1), 71. doi: https://doi.org/10.1038/s41572-024-00551-9
2. Yusuf, M. H. M., Zambri, S. N., Tajuddin, N. A. N. B. A., & Hairi, F. B. M. (2025). Health Impacts of Smoking. doi: https://doi.org/10.5772/intechopen.1010561
3. Ermayanti, S., & Fitrina, D. W. (2022). Effect of radon and lung cancer risk: a narrative literature review. Bioscientia Medicina: Journal of Biomedicine and Translational Research, 6 (15), 2691-2698. doi: https://doi.org/10.37275/bsm.v6i15.669
4. Ganie, F. A., ud Wani, N., & Gani, M. (2025). Exposure to indoor household air pollution and its impact. In Hazardous Chemicals (pp. 765-773). Academic Press. doi: https://doi.org/10.1016/B978-0-323-95235-4.00040-2
5. Chen, P. M., Huang, Y. H., & Li, C. Y. (2026). Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances. Diagnostics, 16 (2), 245. doi: https://doi.org/10.3390/diagnostics16020245
6. Gomez, S. L., DeRouen, M., Chen Jr, M. S., Wakelee, H., Velotta, J. B., Sakoda, L. C., … & Cheng, I. (2025). Elevated risk of lung cancer among Asian American women who have never smoked: an emerging cancer disparity. JNCI: Journal of the National Cancer Institute, 117 (6), 1104-1109.
7. Gavito-Covarrubias, D., Ramírez-Díaz, I., Guzmán-Linares, J., Limón, I. D., Manuel-Sánchez, D. M., Molina-Herrera, A., … & Rubio, K. (2024). Epigenetic mechanisms of particulate matter exposure: air pollution and hazards on human health. Frontiers in Genetics, 14, 1306600. doi: https://doi.org/10.3389/fgene.2023.1306600
8. Gopalakrishnan, N. K., Ansar, S. S., Pappuswamy, M., & Chaudhary, A. (2025). Comparative Analysis of Carcinogenic Compounds in Cooking Oil Emissions and Cigarette Smoke: Implications for Genetic Disorders and Cancer Susceptibility. doi: https://doi.org/10.5772/intechopen.1006096
9. Marie Quinn, A., G Newman, W., & S Hasleton, P. (2016). Risk factors for lung cancer in never smokers: A recent review including genetics. Current Respiratory Medicine Reviews, 12 (1), 74-117.
10. Smolle, E., & Pichler, M. (2019). Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition. Cancers, 11 (2), 204. doi: https://doi.org/10.3390/cancers11020204
11. Campbell, L. (2025). Air Pollution and Epigenetic Modifications: Unveiling the Molecular Mechanisms in Cardiovascular Disease Progression. doi: